Geron Hit Hard by Termination of Phase II Brain Cancer Trial
By Catherine Shaffer
Wednesday, December 5, 2012
Shares of Geron Corp. fell 23 percent Tuesday on news that the Menlo Park, Calif.-based company discontinued development of its brain cancer drug GRN1005.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.